Five by 15 foot test plots of different hybrid wheat strains are grown at the research farm for the bio-technology company Syngenta near Junction City, Kansas, U.S. May 4, 2017. REUTERS/Dave Kaup 

An old barn is surrounded by hybrid wheat test plots outside the bio-technology company Syngenta's research farm near Junction City, Kansas, U.S. May 4, 2017. REUTERS/Dave Kaup 

Nematodes are seen on a monitor connected to a microscope during a photo opportunity at the lab of Hirotsu Bio Science in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. REUTERS/Kim Kyung-Hoon 

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. REUTERS/Kim Kyung-Hoon 

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. REUTERS/Kim Kyung-Hoon 

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio examines nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. REUTERS/Kim Kyung-Hoon 

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio points at nematodes on a monitor connected to a microscope during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. REUTERS/Kim Kyung-Hoon 

Hirotsu Bio Science Chief Technical Officer Eric Di Luccio poses with nematodes in a petri dish during a photo opportunity at the company's lab in Fujisawa, Kanagawa Prefecture, Japan November 28, 2022. REUTERS/Kim Kyung-Hoon 

Pharmacist Thomas Stephan vaccinates a man with a dose of the Pfizer-BioNTech COVID-19 vaccine on the first day trained pharmacies carry out COVID-19 vaccinations in the 'Europa Apotheke' pharmacy amid the corovavirus disease pandemic in Dusseldorf, Germany, February 7, 2022. REUTERS/Thilo Schmuelgen 

Pharmacist Thomas Stephan vaccinates a man with a dose of the Pfizer-BioNTech COVID-19 vaccine on the first day trained pharmacies carry out COVID-19 vaccinations in the 'Europa Apotheke' pharmacy amid the corovavirus disease pandemic in Dusseldorf, Germany, February 7, 2022. REUTERS/Thilo Schmuelgen 

Tomas Lara, 11, receives a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at a vaccination center in San Jose, Costa Rica January 11, 2022. REUTERS/Mayela Lopez 

Tatiana Perez, 11, receives a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at a vaccination center in San Jose, Costa Rica January 11, 2022. REUTERS/Mayela Lopez 

Julian Parra, 11, receives a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at a vaccination center in San Jose, Costa Rica January 11, 2022. REUTERS/Mayela Lopez 

Fiorella Lopez, 11, receives a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at a vaccination center in San Jose, Costa Rica January 11, 2022. REUTERS/Mayela Lopez 

Children, accompanied by their mothers, wait for a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at a vaccination center in San Jose, Costa Rica January 11, 2022. REUTERS/Mayela Lopez 

Parents and their children queue to enter a vaccination center to receive a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine in San Jose, Costa Rica January 11, 2022. REUTERS/Mayela Lopez 

Emma Sevilla, 11, receives a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at a vaccination center in San Jose, Costa Rica January 11, 2022. REUTERS/Mayela Lopez 

Robert Ford, president and CEO of Abbott Laboratories, talks about the company’s Lingo brand of bio-wearable devices during a keynote address at CES 2022 in Las Vegas, Nevada, U.S. January 6, 2022. REUTERS/Steve Marcus 

Robert Ford, president and CEO of Abbott Laboratories, talks about the company’s Lingo brand of bio-wearable devices during a keynote address at CES 2022 in Las Vegas, Nevada, U.S. January 6, 2022. REUTERS/Steve Marcus 

A nurse displays a vial of the Comirnaty by BioNTech/Pfizer vaccine against the coronavirus disease (COVID-19) at a vaccination centre in Berlin, Germany, January 1, 2022. REUTERS/Michele Tantussi 

German Viasus Tibamoso, founder of Tierra Viva, waits for a truck loaded with organic waste that will later be used to produce bio-compost and biofertilizer with the help of beetle larvae, in a production plant, in Tunja, Colombia, October 8, 2021. Picture taken October 8, 2021. REUTERS/Luisa Gonzalez 

Beetle larvae are seen on organic waste covered with soil to produce bio-compost, at Tierra Viva's production plant, in Tunja, Colombia, October 8, 2021. Picture taken October 8, 2021. REUTERS/Luisa Gonzalez 

A Tierra Viva worker excavates organic waste that will later be used to produce bio-compost and bio-fertilizer with the help of beetle larvae at a production plant in Tunja, Colombia, October 8, 2021. Picture taken October 8, 2021. REUTERS/Luisa Gonzalez 

Organic waste that will later be used to produce bio-compost and bio-fertilizer with the help of beetle larvae collected by Tierra Viva is seen in its compost production plant in Tunja, Colombia, October 8, 2021. Picture taken October 8, 2021. REUTERS/Luisa Gonzalez 

Beetles, which are sold as pets to several countries around the world and traded with the Kmushicoin cryptocurrency created by Tierra Viva, climb a trunk at the company's production plant, where bio-compost and bio-fertilizer are produced, in Tunja, Colombia, October 8, 2021. Picture taken October 8, 2021. REUTERS/Luisa Gonzalez 

Beetles, which are sold as pets to several countries around the world and traded with the Kmushicoin cryptocurrency created by Tierra Viva, climb a trunk at the company's production plant, where bio-compost and bio-fertilizer are produced, in Tunja, Colombia, October 8, 2021. Picture taken October 8, 2021. REUTERS/Luisa Gonzalez 

U.S. ecretary of State Antony Blinken gestures to researchers working in bio-containment laboratories for highly infectious pathogens as he is escorted by Paul Duprex, PhD, director of University of Pittsburgh’s Center for Vaccine Research, on a tour at the ARGO facility during a meeting of the United States-European Union Trade and Technology Council (TTC), in Pittsburgh, Pennsylvania, U.S., September 30, 2021. Rebecca Droke/Pool via REUTERS 

Dina Radenkovic, Partner at the SALT Bio Fund and Chief Science Officer of the Hooke longevity clinic, speaks during the Skybridge Capital SALT New York 2021 conference in New York City, U.S., September 13, 2021. REUTERS/Brendan McDermid 

CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen attend a meeting in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO of kENUP Foundation, Holm Keller, CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen pose for a family photo with Rwanda's President Paul Kagame and Senegal's President Macky Sall in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO and co-founder of BioNTech, Ugur Sahin attends a meeting in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen attend a meeting in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen attend a meeting in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO and co-founder of BioNTech, Ugur Sahin speaks next to European Commission President Ursula von der Leyen during a meeting in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen wear face masks during a meeting in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen attend a meeting in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen attend a meeting in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen bump fists during a meeting in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO of kENUP Foundation, Holm Keller, CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen meet with Rwanda's President Paul Kagame and Senegal's President Macky Sall in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO of kENUP Foundation, Holm Keller, CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen meet with Rwanda's President Paul Kagame and Senegal's President Macky Sall in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

CEO of kENUP Foundation, Holm Keller, CEO and co-founder of BioNTech, Ugur Sahin and European Commission President Ursula von der Leyen meet with Rwanda's President Paul Kagame and Senegal's President Macky Sall in Berlin, Germany, August 27, 2021. REUTERS/Michele Tantussi 

A medical worker in a school hall administers a dose of the Pfizer-BioNTech COVID-19 vaccine to a student of the Leibniz-Montessori secondary school, amid the coronavirus disease (COVID-19) pandemic, in Dusseldorf, Germany, August 27, 2021. REUTERS/Thilo Schmuelgen 

A medical worker in a school hall administers a dose of the Pfizer-BioNTech COVID-19 vaccine to a student of the Leibniz-Montessori secondary school, amid the coronavirus disease (COVID-19) pandemic, in Dusseldorf, Germany, August 27, 2021. REUTERS/Thilo Schmuelgen 

A medical worker in a school hall administers a dose of the Pfizer-BioNTech COVID-19 vaccine to a student of the Leibniz-Montessori secondary school, amid the coronavirus disease (COVID-19) pandemic, in Dusseldorf, Germany, August 27, 2021. REUTERS/Thilo Schmuelgen 

Ozlem Tureci and her husband Ugur Sahin, both German scientists, CEOs and founders of BioNTech, Oliver Hennig, Senior Vice President Operations and German Chancellor Angela Merkel visit the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

CEO and co-founder of BioNTech, Ugur Sahin welcomes German Chancellor Angela Merkel before a visit of the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

CEO and co-founder of BioNTech, Ugur Sahin welcomes German Chancellor Angela Merkel before a visit of the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

CEO and co-founder of BioNTech, Ugur Sahin welcomes German Chancellor Angela Merkel before a visit of the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

German Chancellor Angela Merkel visits the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

German Chancellor Angela Merkel visits the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

German Chancellor Angela Merkel visits the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

Ozlem Tureci and her husband Ugur Sahin, both German scientists, CEOs and founders of BioNTech wait for the arrival of German Chancellor Angela Merkel before a visit of the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

German Chancellor Angela Merkel visits the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

Ozlem Tureci and her husband Ugur Sahin, both German scientists, CEOs and founders of BioNTech, German Chancellor Angela Merkel and Helge Braun visit the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

Ozlem Tureci and her husband Ugur Sahin, both German scientists, CEOs and founders of BioNTech and German Chancellor Angela Merkel visit the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

Ozlem Tureci and her husband Ugur Sahin, both German scientists, CEOs and founders of BioNTech and German Chancellor Angela Merkel visit the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

Ozlem Tureci and her husband Ugur Sahin, both German scientists, CEOs and founders of BioNTech and German Chancellor Angela Merkel visit the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

Ozlem Tureci and her husband Ugur Sahin, both German scientists, CEOs and founders of BioNTech and German Chancellor Angela Merkel visit the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

Ozlem Tureci and her husband Ugur Sahin, both German scientists, CEOs and founders of BioNTech and German Chancellor Angela Merkel visit the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters 

Ozlem Tureci and her husband Ugur Sahin, both German scientists, CEOs and founders of BioNTech and German Chancellor Angela Merkel visit the BioNTech COVID-19 mRNA vaccine production facility in Marburg, Germany, August 19, 2021. Arne Dedert/Pool via Reuters